Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Pragmatiston Aug 10, 2020 3:08am
276 Views
Post# 31386026

RE:RE:RE:John Wallace OP-ed Chicago Tribune

RE:RE:RE:John Wallace OP-ed Chicago Tribune
Marky1 wrote: Thank you Popeye! Great find...My question, to anyone here, when they say evaluation is 3$.....What time frame are they talking about?? Thank you!

Hello Marky.  Crow said one year.  This is normally a good benchmark, but that time frame usually applies to seasoned  companies with established records of earnings.  For these stocks, analysts typically  look at 12 month trailing earnings, divided by the number of outstanding shares, and multiplied by a factor to reflect continued earnings/growth.  Historical averages (this factor)  for most exchanges is approx 15-16x. Varies with the company/current market sentiment.
 
But Antibe is not a seasoned stock.  It has no current or expected near term earnings. There are no quantitative metrics to establish near term share price.   I suspect that posted target share price is based on net present  value (that is, expected future earinings, risk adjusted, and discounted to present value)  over a much longer time frame, i.e., the length of the patent.  Don't know.  Tried unsuccessfully to research this. No luck.  But nothing else makes sense.
 
So don't get hooked on the timing of analyst's share price. My best guess is that it is an estimate of current value of the company based on NPV.  May or may not reflect the value that the company could sell for today.  But almost certaintly to change with time. Just my opinion.
Bullboard Posts